North America Radioimmunoassay Market
Market Size in USD Billion
CAGR :
% 
 Forecast Period |
2024 –2030 |
 Market Size (Base Year) |
|
 Market Size (Forecast Year) |
USD 407.20 |
 CAGR |
% |
| Major Markets Players |
North America Radioimmunoassay Market, By Product Type (Radio Immunoassay Reagents and Kits and Radio Immunoassay Analyser), Application (Scientific Research and Clinical Diagnosis), End User (Hospitals, Clinical Diagnostic Laboratories, Academic and Research Institutes, Pharmaceutical and Biopharmaceutical Industry, Contract Research Organizations, and Other), Distribution Channel (Direct Tender, Online Sales, Third Party Distribution, and Others) Industry Trends and Forecast to 2030.
North America Radioimmunoassay Market Analysis and Insights
Due to the rise in healthcare prevalence of various diseases, increased research in the healthcare sector for therapeutic purposes, and various testing like endocrinology and infectious diseases by using radioimmunoassay kits which are used for testing, as well as increasing healthcare spending would also propel business growth. The clinical research and laboratories for pre-testing various diseases allow the market to expand.
The North America radioimmunoassay market is expected to grow in the forecast period of 2023 to 2030. Data Bridge Market Research analyses that the market is growing with a CAGR of 4.4% in the forecast period of 2023 to 2030 and is expected to reach USD 407.2 million by 2030.
|
Report Metric |
Details |
|
Forecast Period |
2023 to 2030 |
|
Base Year |
2022 |
|
Historic Years |
2021 (Customisable to 2020-2016) |
|
Quantitative Units |
Revenue in USD Million |
|
Segments Covered |
By Product Type (Radio Immunoassay Reagents and Kits and Radio Immunoassay Analyser), Application (Scientific Research and Clinical Diagnosis), End User (Hospitals, Clinical Diagnostic Laboratories, Academic and Research Institutes, Pharmaceutical and Biopharmaceutical Industry, Contract Research Organizations, and Other), Distribution Channel (Direct Tender, Online Sales, Third Party Distribution, and Others). |
|
Countries Covered |
U.S., Canada, and Mexico |
|
Market Players Covered |
The major companies which are dealing in the market are PerkinElmer Inc., KAMIYA BIOMEDICAL COMPANY, Beckman Coulter, Inc., and Abcam plc. MyBioSource.com., and MP BIOMEDICALS, Tecan Trading AG, among others. |
Market Definition
Radioimmunoassay is a heterogeneous assay that employs a radiolabeled drug (typically 125i), the competitive binding assay theory that underpins radioimmunoassay. In this method, antigen and antibody bind to one another, and radioimmunoassay is used to determine how much antigen is bound. With the aid of antibodies, this method's hypersensitivity allows it to detect even the tiniest hormone or medication levels.
Due to the rise in healthcare prevalence of various diseases, increased research in the healthcare sector for therapeutic purposes, and various testing like endocrinology and infectious diseases by using radioimmunoassay kits used for testing and increasing healthcare spending would also propel business growth. The clinical research and laboratories for pre-testing various diseases allow the market to expand.
With this increasing number of such severe diseases like cancer and infections and healthcare awareness, the growth of laboratory testing has led to increased demand for various kits for testing. This aspect also contributes to the rising demand for reagents and kits.
The North America radioimmunoassay market is growing in the forecast year due to the rise in market players and the availability of advanced kits and analyzers. Along with this, manufacturers are engaged in R&D activity for launching products in the market. The increasing research and developments and pre-testing further boost the market growth. However, another immunoassay testing technique dominates radioimmunoassay, which might hamper the growth of the North America radioimmunoassay market in the forecast period.
North America Radioimmunoassay Market Dynamics
This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
INCREASE IN THE DEMAND FOR ERROR-FREE AND ACCURATE RESULTS OF HIGH THROUGHPUT AND AUTOMATED PROCEDURES
Radioimmunoassay is a heterogeneous assay that employs a radiolabeled drug (typically 125i), the competitive binding assay theory that underpins radioimmunoassay. In this method, antigen and antibody bind to one another, and radioimmunoassay is used to determine how much antigen is bound.
Therefore, due to the increasing number of such severe diseases and viruses, the growth of biological models has been largely seen in recent years. This has increased the demand for error-free and accurate results from biological samples.
RISE IN THE PREVALENCE AND INCIDENCE OF INFECTIOUS DISEASES
Infectious diseases are illnesses caused by harmful agents (pathogens) entering the body. The most common causes are viruses, bacteria, fungi, and parasites. Infectious diseases usually spread from person to person through contaminated food or water and bug bites. Some infectious diseases are minor, and some are very serious.
Thus, rising number of cases of infectious, the growth of biological models has been largely seen in recent years. This has led to increased demand for various radioimmunoassay techniques for detecting and studying these aspects, which is expected to drive the market's growth in the coming years.
Restraints
HIGH COST OF INSTALLATION AND MAINTENANCE OF RADIOIMMUNOASSAY KITS
The cost of radioimmunoassay kits is a major setback for the market as it is expected to decrease the demand due to high costs.
Therefore, increasing research and development in the life science domain leads to more advancement in radioimmunoassay techniques. That advancement is continuously increasing the price of the radioimmunoassay and its units, which may hamper the growth of the North America radioimmunoassay market.
SHORT SHELF-LIFE OF RADIOLABELED COMPOUNDS
Chemical compounds decompose over time during storage. The rate at which this takes place is specific to the compound. However, compounds labeled with radioisotopes typically decompose faster than their unlabeled counterparts due to radiolytic decomposition.
Hence, the utmost care needed to be taken for the storage usage of radiolabelled isotopes in radioimmunoassay techniques for its prevention from decomposition act as a restraining factor for the North America radioimmunoassay market.
Opportunities/Challenges
LACK OF SKILLED PROFESSIONALS
The radioimmunoassay technique is very advanced and sensitive enough to find small molecules in the blood. It is therefore used for research purposes and diagnosing diseases such as cancer. Organizations and research labs also implement this technique for specific research purposes that use animal or human serum. However, the lack of qualified personnel who cannot use these instruments could curb the growth of the radioimmunoassay market over a forecast period.
Moreover, rapid technological advancement in this field also led to the lack of skilled professionals. Lack of skilled professionals poses a major challenge while handling device devices worldwide.
Recent Developments
- In April 2022, Merck, a leading science and technology company, announced several organizational changes and a new operating model to support the life science business sector's long-term growth strategy and better serve its customers' evolving needs. This has helped the company to expand its life sciences business segment.
- In June 2022, EUROIMMUN, a PerkinElmer, Inc. company, announced the launch of two CE-marked assays – the Anti-SARS-CoV-2 RBD ChLIA (IgG) and the Anti-SARS-CoV-2 Omicron ELISA (IgG). Both test systems enable the detection of IgG antibodies formed against SARS-CoV-2 and are available to laboratories in countries that accept the CE mark. This has helped the company to expand its business in the market.
North America Radioimmunoassay Market Scope
North America radioimmunoassay market is segmented into product type, application, end user, and distribution channel. The growth amongst these segments will help you analyze major growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
By Product Type
- Radio Immunoassay Reagents and Kits
- Radio Immunoassay Analyzer
On the basis of product type, the North America radioimmunoassay market is segmented into radio immunoassay reagents and kits and radio immunoassay analyzer.
By Application
- Clinical Diagnosis
- Scientific Research
On the basis of application, the North America radioimmunoassay market is segmented into clinical diagnosis and scientific research.
By End user
- Hospitals
- Clinical Diagnostic Laboratories
- Academic And Research Institutes
- Pharmaceutical And Biopharmaceutical Industry
- Contract Research Organizations
- Others
On the basis of end user, the North America radioimmunoassay market is segmented into hospitals, clinical diagnostic laboratories, academic and research institutes, pharmaceutical and biopharmaceutical industry, contract research organisations, and others.
By Distribution Channel
- Direct Tender
- Online Sales
- Third Party Distributions
- Others
On the basis of distribution channel, the North America radioimmunoassay market is segmented into direct tender, online sales, third party distributions and others.
North America Radioimmunoassay Market Regional Analysis/Insights
The North America radioimmunoassay market is analyzed, and market size insights and trends are provided by product type, application, end user, and distribution channel, as referenced above.
The countries covered in the report are U.S., Canada, and Mexico.
U.S. dominates the North America radioimmunoassay market regarding market share and revenue and will continue to flourish its dominance during the forecast period. This is due to the rising technological advancements in microscopy in that region, and growing R&D investments and the launch of new products are boosting the market
The country section of the report also provides individual market-impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, disease epidemiology, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of North America brands and their challenges faced due to competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and North America Radioimmunoassay Market Share Analysis
The competitive radioimmunoassay landscape provides details by a competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, North America presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points are only related to the companies focusing on the radioimmunoassay market.
Some of the major players operating in the North America radioimmunoassay Market are PerkinElmer Inc., KAMIYA BIOMEDICAL COMPANY, Beckman Coulter, Inc., Abcam plc., MyBioSource.com., MP BIOMEDICALS, and Tecan Trading AG, among others.
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA RADIOIMMUNOASSAY MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET TESTING TYPE COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTYER’S FIVE FORCES
4.3 GROWTH STRATEGIES ADOPTED BY KEY MARKET PLAYERS
5 INDUSTRY INSIGHTS:
6 REGULATORY GUIDELINES FOR RADIOIMMUNOASSAY
6.1 U.S REGULATORY GUIDELINES FOR RADIOIMMUNOASSAY
6.2 EUROPE REGULATORY GUIDELINE FOR RADIOIMMUNOASSAY
6.3 INDIA REGULATORY GUIDELINE FOR RADIOIMMUNOASSAY
6.4 CHINA REGULATORY GUIDELINE FOR RADIOIMMUNOASSAY
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASE IN THE DEMAND FOR ERROR-FREE AND ACCURATE RESULTS OF HIGH THROUGHPUT AND AUTOMATED PROCEDURES
7.1.2 RISE IN THE PREVALENCE AND INCIDENCE OF INFECTIOUS DISEASES
7.1.3 RISE IN THE TECHNOLOGICAL ADVANCEMENTS
7.2 RESTRAINTS
7.2.1 HIGH COST OF INSTALLATION AND MAINTENANCE OF RADIOIMMUNOASSAY KITS
7.2.2 SHORT SHELF-LIFE OF RADIOLABELED COMPOUNDS
7.2.3 ADVERSE EFFECTS OF HAZARDOUS RADIOACTIVE ELEMENTS
7.3 OPPORTUNITIES
7.3.1 INCREASING SIGNIFICANCE OF RESEARCH AND DEVELOPMENT IN MEDICAL SCIENCE
7.3.2 RISE IN GOVERNMENT FUNDING AND OVERALL HEALTHCARE EXPENDITURE
7.3.3 STRATEGIC INITIATIVES BY MARKET PLAYERS
7.4 CHALLENGES
7.4.1 LACK OF SKILLED PROFESSIONALS
7.4.2 NEW INNOVATIONS IN VARIOUS OTHER IMMUNOASSAY PROCEDURES
8 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE
8.1 OVERVIEW
8.2 RADIOIMMUNOASSAY REAGENTS AND KITS
8.2.1 KITS
8.2.2 BUFFER
8.2.2.1 SOLUTION
8.2.2.2 POWDER
8.2.3 STANDARD CONCENTRATES
8.2.4 PRECIPITATING REAGENTS
8.2.5 RADIOISOTOPES
8.2.5.1 BETA EMITTERS
8.2.5.1.1 TRITIUM
8.2.5.1.2 CARBON-14
8.2.5.2 GAMMA EMITTERS
8.2.5.2.1 IODINE-125
8.2.5.2.2 CHROMIUM-51
8.2.5.2.3 COBALT-57
8.2.6 ANTIBODY/ANTISERUM
8.2.6.1 POLYCLONAL
8.2.6.2 MONOCLONAL
8.2.7 OTHERS
8.3 RADIOIMMUNOASSAY ANALYZER
9 NORTH AMERICA RADIOIMMUNOASSAY MARKET: BY APPLICATION
9.1 OVERVIEW
9.2 SCIENTIFIC RESEARCH
9.2.1 RADIOIMMUNOASSAY REAGENTS AND KITS
9.2.2 RADIOIMMUNOASSAY ANALYZER
9.3 CLINICAL DIAGNOSIS
9.3.1 INFECTIOUS DISEASE TESTING
9.3.1.1 RADIOIMMUNOASSAY REAGENTS AND KITS
9.3.1.2 RADIOIMMUNOASSAY ANALYZER
9.3.2 ALLERGY TESTING
9.3.2.1 RADIOIMMUNOASSAY REAGENTS AND KITS
9.3.2.2 RADIOIMMUNOASSAY ANALYZER
9.3.3 ONCOLOGY TESTING
9.3.3.1 RADIOIMMUNOASSAY REAGENTS AND KITS
9.3.3.2 RADIOIMMUNOASSAY ANALYZER
9.3.4 ENDOCRINE TESTING
9.3.4.1 RADIOIMMUNOASSAY REAGENTS AND KITS
9.3.4.2 RADIOIMMUNOASSAY ANALYZER
9.3.5 TOXICOLOGY TESTING
9.3.5.1 RADIOIMMUNOASSAY REAGENTS AND KITS
9.3.5.2 RADIOIMMUNOASSAY ANALYZER
9.3.6 AUTOIMMUNE DISEASE TESTING
9.3.6.1 RADIOIMMUNOASSAY REAGENTS AND KITS
9.3.6.2 RADIOIMMUNOASSAY ANALYZER
9.3.7 OTHER DISEASE TESTING
10 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY END USER
10.1 OVERVIEW
10.2 HOSPITALS
10.3 CLINICAL DIAGNOSTIC LABORATORIES
10.4 ACADEMIC AND RESEARCH INSTITUTES
10.5 PHARMACEUTICAL AND BIOPHARMACEUTICAL INDUSTRY
10.6 CONTRACT RESEARCH ORGANISATIONS
10.7 OTHERS
11 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY DISTRIBUTION CHANNEL
11.1 OVERVIEW
11.2 DIRECT TENDER
11.3 ONLINE SALES
11.4 THIRD PARTY DISTRIBUTIONS
11.5 OTHERS
12 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY REGION
12.1 NORTH AMERICA
12.1.1 U.S.
12.1.2 CANADA
12.1.3 MEXICO
13 NORTH AMERICA RADIOIMMUNOASSAY MARKET: COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
14 SWOT ANALYSIS
15 COMPANY PROFILE
15.1 PERKINELMER INC.
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 COMPANY SHARE ANALYSIS
15.1.4 PRODUCT PORTFOLIO
15.1.4 RECENT DEVELOPMENT
15.2 MERCK KGAA
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 COMPANY SHARE ANALYSIS
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPMENTS
15.3 BECKMAN COULTER, INC.
15.3.1 COMPANY SNAPSHOT
15.3.2 COMPANY SHARE ANALYSIS
15.3.3 PRODUCT PORTFOLIO
15.3.4 RECENT DEVELOPMENT
15.4 ABCAM PLC
15.4.1 COMPANY SNAPSHOT
15.4.2 REVENUE ANALYSIS
15.4.3 COMPANY SHARE ANALYSIS
15.4.4 PRODUCT PORTFOLIO
15.4.5 RECENT DEVELOPMENT
15.5 TECAN TRADING AG
15.5.1 COMPANY SNAPSHOT
15.5.2 REVENUE ANALYSIS
15.5.3 COMPANY SHARE ANALYSIS
15.5.4 PRODUCT PORTFOLIO
15.5.5 RECENT DEVELOPMENT
15.6 BERTHOLD TECHNOLOGIES GMBH & CO.KG
15.6.1 COMPANY SNAPSHOT
15.6.2 PRODUCT PORTFOLIO
15.6.3 RECENT DEVELOPMENTS
15.7 DEMEDITEC DIAGNOSTICS GMBH
15.7.1 COMPANY SNAPSHOT
15.7.2 PRODUCT PORTFOLIO
15.7.3 RECENT DEVELOPMENTS
15.8 DIASOURCE
15.8.1 COMPANY SNAPSHOT
15.8.2 PRODUCT PORTFOLIO
15.8.3 RECENT DEVELOPMENT
15.9 EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG
15.9.1 COMPANY SNAPSHOT
15.9.2 PRODUCT PORTFOLIO
15.9.3 RECENT DEVELOPMENTS
15.1 HIDEX OY
15.10.1 COMPANY SNAPSHOT
15.10.2 PRODUCT PORTFOLIO
15.10.3 RECENT DEVELOPMENTS
15.11 IMMUNO-BIOLOGICAL LABORATORIES CO,LTD.
15.11.1 COMPANY SNAPSHOT
15.11.2 PRODUCT PORTFOLIO
15.11.3 RECENT DEVELOPMENT
15.12 INSTITUTE OF ISOTOPES
15.12.1 COMPANY SNAPSHOT
15.12.2 PRODUCT PORTFOLIO
15.12.3 RECENT DEVELOPMENTS
15.13 KAMIYA BIOMEDICAL COMPANY
15.13.1 COMPANY SNAPSHOT
15.13.2 PRODUCT PORTFOLIO
15.13.3 RECENT DEVELOPMENTS
15.14 MP BIOMEDICALS
15.14.1 COMPANY SNAPSHOT
15.14.2 PRODUCT PORTFOLIO
15.14.3 RECENT DEVELOPMENTS
15.15 MYBIOSOURCE.COM.
15.15.1 COMPANY SNAPSHOT
15.15.2 PRODUCT PORTFOLIO
15.15.3 RECENT DEVELOPMENT
16 QUESTIONNAIRE
17 RELATED REPORTS
List of Table
TABLE 1 LIST OF IN-VITRO DIAGNOSTIC MEDICAL DEVICES (IVD ANALYZERS) UNDER PROVISIONS OF SUB-RULE (2) RULE 4 OF THE MEDICAL DEVICES RULES, 2017
TABLE 2 COST OF RIA KITS IS MENTIONED BELOW
TABLE 3 DECOMPOSITION RATES OF A FEW RADIOLABELED ISOTOPES ARE MENTIONED IN THE BELOW TABLE
TABLE 4 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 5 NORTH AMERICA RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 6 NORTH AMERICA RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 7 NORTH AMERICA BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 8 NORTH AMERICA RADIOISOTOPES IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 9 NORTH AMERICA BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 10 NORTH AMERICA GAMMA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 11 NORTH AMERICA ANTIBODY/ANTISERUM IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 12 NORTH AMERICA RADIOIMMUNOASSAY ANALYZER IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 13 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 14 NORTH AMERICA SCIENTIFIC RESEARCH IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 15 NORTH AMERICA SCIENTIFIC RESEARCH IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 16 NORTH AMERICA CLINICAL DIAGNOSIS IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 17 NORTH AMERICA CLINICAL DIAGNOSIS IN RADIOIMMUNOASSAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 18 NORTH AMERICA INFECTIOUS DISEASE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 19 NORTH AMERICA ALLERGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 20 NORTH AMERICA ONCOLOGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 21 NORTH AMERICA ENDOCRINE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 22 NORTH AMERICA TOXICOLOGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE 2021-2030 (USD MILLION)
TABLE 23 NORTH AMERICA AUTOIMMUNE DISEASE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 24 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 25 NORTH AMERICA HOSPITALS IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 NORTH AMERICA CLINICAL DIAGNOSTIC LABORATORIES IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 27 NORTH AMERICA ACADEMIC AND RESEARCH INSTITUTES IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 28 NORTH AMERICA PHARMACEUTICAL AND BIOPHARMACEUTICAL INDUSTRY IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 29 NORTH AMERICA CONTRACT RESEARCH ORGANISATIONS IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 30 NORTH AMERICA OTHERS IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 31 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 32 NORTH AMERICA DIRECT TENDER IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 33 NORTH AMERICA ONLINE SALES IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 34 NORTH AMERICA THIRD PARTY DISTRIBUTION IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 35 NORTH AMERICA OTHERS IN RADIOIMMUNOASSAY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 36 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 37 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 38 NORTH AMERICA RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 39 NORTH AMERICA RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME)
TABLE 40 NORTH AMERICA RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD)
TABLE 41 NORTH AMERICA BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 42 NORTH AMERICA BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME)
TABLE 43 NORTH AMERICA BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD)
TABLE 44 NORTH AMERICA RADIOISOTOPES IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 45 NORTH AMERICA BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 46 NORTH AMERICA BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME)
TABLE 47 NORTH AMERICA BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD)
TABLE 48 NORTH AMERICA GAMMA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 49 NORTH AMERICA GAMMA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME)
TABLE 50 NORTH AMERICA GAMMA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD)
TABLE 51 NORTH AMERICA ANTIBODY/ANTISERUM IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030(USD MILLION)
TABLE 52 NORTH AMERICA ANTIBODY/ANTISERUM IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030(VOLUME)
TABLE 53 NORTH AMERICA ANTIBODY/ANTISERUM IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030(ASP IN USD)
TABLE 54 NORTH AMERICA RADIO IMMUNO ANALYZERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME)
TABLE 55 NORTH AMERICA RADIO IMMUNO ANALYZERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD)
TABLE 56 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 57 NORTH AMERICA SCIENTIFIC RESEARCH IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 58 NORTH AMERICA CLINICAL DIAGNOSIS IN RADIOIMMUNOASSAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 59 NORTH AMERICA INFECTIOUS DISEASE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 60 NORTH AMERICA ALLERGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 61 NORTH AMERICA ONCOLOGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 62 NORTH AMERICA ENDOCRINE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 63 NORTH AMERICA TOXICOLOGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE 2021-2030 (USD MILLION)
TABLE 64 NORTH AMERICA AUTOIMMUNE DISEASE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 65 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 66 NORTH AMERICA RADIOIMMUNOASSAY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 67 U.S. RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 68 U.S. RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 69 U.S. RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME)
TABLE 70 U.S. RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD)
TABLE 71 U.S. BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 72 U.S. BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME)
TABLE 73 U.S. BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD)
TABLE 74 U.S. RADIOISOTOPES IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 75 U.S. BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 76 U.S. BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME)
TABLE 77 U.S. BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD)
TABLE 78 U.S. GAMMA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 79 U.S. GAMMA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME)
TABLE 80 U.S. GAMMA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD)
TABLE 81 U.S. ANTIBODY/ANTISERUM IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030(USD MILLION)
TABLE 82 U.S. ANTIBODY/ANTISERUM IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030(VOLUME)
TABLE 83 U.S. ANTIBODY/ANTISERUM IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030(ASP IN USD)
TABLE 84 U.S. RADIO IMMUNO ANALYZERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME)
TABLE 85 U.S. RADIO IMMUNO ANALYZERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD)
TABLE 86 U.S. RADIOIMMUNOASSAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 87 U.S. SCIENTIFIC RESEARCH IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 88 U.S. CLINICAL DIAGNOSIS IN RADIOIMMUNOASSAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 89 U.S. INFECTIOUS DISEASE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 90 U.S. ALLERGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 91 U.S. ONCOLOGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 92 U.S. ENDOCRINE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 93 U.S. TOXICOLOGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE 2021-2030 (USD MILLION)
TABLE 94 U.S. AUTOIMMUNE DISEASE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 95 U.S. RADIOIMMUNOASSAY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 96 U.S. RADIOIMMUNOASSAY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 97 CANADA RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 98 CANADA RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 99 CANADA RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME)
TABLE 100 CANADA RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD)
TABLE 101 CANADA BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 102 CANADA BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME)
TABLE 103 CANADA BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD)
TABLE 104 CANADA RADIOISOTOPES IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 105 CANADA BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 106 CANADA BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME)
TABLE 107 CANADA BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD)
TABLE 108 CANADA GAMMA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 109 CANADA GAMMA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME)
TABLE 110 CANADA GAMMA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD)
TABLE 111 CANADA ANTIBODY/ANTISERUM IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030(USD MILLION)
TABLE 112 CANADA ANTIBODY/ANTISERUM IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030(VOLUME)
TABLE 113 CANADA ANTIBODY/ANTISERUM IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030(ASP IN USD)
TABLE 114 CANADA RADIO IMMUNO ANALYZERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME)
TABLE 115 CANADA RADIO IMMUNO ANALYZERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD)
TABLE 116 CANADA RADIOIMMUNOASSAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 117 CANADA SCIENTIFIC RESEARCH IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 118 CANADA CLINICAL DIAGNOSIS IN RADIOIMMUNOASSAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 119 CANADA INFECTIOUS DISEASE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 120 CANADA ALLERGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 121 CANADA ONCOLOGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 122 CANADA ENDOCRINE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 123 CANADA TOXICOLOGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE 2021-2030 (USD MILLION)
TABLE 124 CANADA AUTOIMMUNE DISEASE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 125 CANADA RADIOIMMUNOASSAY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 126 CANADA RADIOIMMUNOASSAY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 127 MEXICO RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 128 MEXICO RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 129 MEXICO RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME)
TABLE 130 MEXICO RADIOIMMUNOASSAY REAGENTS AND KITS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD)
TABLE 131 MEXICO BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 132 MEXICO BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME)
TABLE 133 MEXICO BUFFER IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD)
TABLE 134 MEXICO RADIOISOTOPES IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 135 MEXICO BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 136 MEXICO BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME)
TABLE 137 MEXICO BETA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD)
TABLE 138 MEXICO GAMMA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 139 MEXICO GAMMA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME)
TABLE 140 MEXICO GAMMA EMITTERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD)
TABLE 141 MEXICO ANTIBODY/ANTISERUM IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030(USD MILLION)
TABLE 142 MEXICO ANTIBODY/ANTISERUM IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030(VOLUME)
TABLE 143 MEXICO ANTIBODY/ANTISERUM IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030(ASP IN USD)
TABLE 144 MEXICO RADIO IMMUNO ANALYZERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME)
TABLE 145 MEXICO RADIO IMMUNO ANALYZERS IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (ASP IN USD)
TABLE 146 MEXICO RADIOIMMUNOASSAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 147 MEXICO SCIENTIFIC RESEARCH IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 148 MEXICO CLINICAL DIAGNOSIS IN RADIOIMMUNOASSAY MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 149 MEXICO INFECTIOUS DISEASE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 150 MEXICO ALLERGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 151 MEXICO ONCOLOGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 152 MEXICO ENDOCRINE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 153 MEXICO TOXICOLOGY TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE 2021-2030 (USD MILLION)
TABLE 154 MEXICO AUTOIMMUNE DISEASE TESTING IN RADIOIMMUNOASSAY MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 155 MEXICO RADIOIMMUNOASSAY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 156 MEXICO RADIOIMMUNOASSAY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
List of Figure
FIGURE 1 NORTH AMERICA RADIOIMMUNOASSAY MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA RADIOIMMUNOASSAY MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA RADIOIMMUNOASSAY MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA RADIOIMMUNOASSAY MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA RADIOIMMUNOASSAY: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA RADIOIMMUNOASSAY MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA RADIOIMMUNOASSAY MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA RADIOIMMUNOASSAY MARKET: MARKET TESTING TYPE COVERAGE GRID
FIGURE 9 NORTH AMERICA RADIOIMMUNOASSAY MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA RADIOIMMUNOASSAY MARKET: SEGMENTATION
FIGURE 11 RISING PREVALENCE AND INCIDENCE OF INFECTIOUS DISEASES ARE EXPECTED TO DRIVE THE NORTH AMERICA RADIOIMMUNOASSAY MARKET IN THE FORECAST PERIOD
FIGURE 12 PRODUCT TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA RADIOIMMUNOASSAY MARKET IN 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA RADIOIMMUNOASSAY MARKET
FIGURE 14 NORTH AMERICA RADIOIMMUNOASSAY MARKET: BY PRODUCT TYPE, 2022
FIGURE 15 NORTH AMERICA RADIOIMMUNOASSAY MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION)
FIGURE 16 NORTH AMERICA RADIOIMMUNOASSAY MARKET: BY PRODUCT TYPE, CAGR (2023-2030)
FIGURE 17 NORTH AMERICA RADIOIMMUNOASSAY MARKET: PRODUCT TYPE, LIFELINE CURVE
FIGURE 18 NORTH AMERICA RADIOIMMUNOASSAY MARKET: BY APPLICATION, 2022
FIGURE 19 NORTH AMERICA RADIOIMMUNOASSAY MARKET: BY APPLICATION, 2023-2030 (USD MILLION)
FIGURE 20 NORTH AMERICA RADIOIMMUNOASSAY MARKET: BY APPLICATION, CAGR (2023-2030)
FIGURE 21 NORTH AMERICA RADIOIMMUNOASSAY MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 22 NORTH AMERICA RADIOIMMUNOASSAY MARKET: BY END USER, 2022
FIGURE 23 NORTH AMERICA RADIOIMMUNOASSAY MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 24 NORTH AMERICA RADIOIMMUNOASSAY MARKET: BY END USER, CAGR (2023-2030)
FIGURE 25 NORTH AMERICA RADIOIMMUNOASSAY MARKET : BY END USER, LIFELINE CURVE
FIGURE 26 NORTH AMERICA RADIOIMMUNOASSAY MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 27 NORTH AMERICA RADIOIMMUNOASSAY MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 28 NORTH AMERICA RADIOIMMUNOASSAY MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 29 NORTH AMERICA RADIOIMMUNOASSAY MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 30 NORTH AMERICA RADIOIMMUNOASSAY MARKET: SNAPSHOT (2022)
FIGURE 31 NORTH AMERICA RADIOIMMUNOASSAY MARKET: BY COUNTRY (2022)
FIGURE 32 NORTH AMERICA RADIOIMMUNOASSAY MARKET: BY COUNTRY (2023 & 2030)
FIGURE 33 NORTH AMERICA RADIOIMMUNOASSAY MARKET: BY COUNTRY (2022 & 2030)
FIGURE 34 NORTH AMERICA RADIOIMMUNOASSAY MARKET: PRODUCT TYPE (2023-2030)
FIGURE 35 NORTH AMERICA RADIOIMMUNOASSAY MARKET: COMPANY SHARE 2022 (%)
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
